We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

FLEX Arteriovenous Access Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04070365
Recruitment Status : Completed
First Posted : August 28, 2019
Last Update Posted : May 31, 2022
Information provided by (Responsible Party):
VentureMed Group Inc.

Brief Summary:
Evaluation of the FLEX Vessel Prep system combined with angioplasty in the treatment of arteriovenous access stenosis.

Condition or disease Intervention/treatment
Peripheral Artery Disease Arteriovenous Fistula Stenosis Arteriovenous Graft Stenosis Device: FLEX Vessel Prep System followed by angioplasty

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 114 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: FLEX Arteriovenous Access Registry
Actual Study Start Date : May 28, 2018
Actual Primary Completion Date : June 9, 2021
Actual Study Completion Date : May 26, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angioplasty

Group/Cohort Intervention/treatment
FLEX Vessel Prep followed by angioplasty Device: FLEX Vessel Prep System followed by angioplasty
Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
Other Name: Balloon Angioplasty

Primary Outcome Measures :
  1. Anatomic Success [ Time Frame: At the completion of the index procedure ]
    Defined as the angiographic percentage of stenosis post procedure as <30%

Secondary Outcome Measures :
  1. Technical Success of the Device [ Time Frame: At the index procedure ]
    Delivery to the target lesion, deployment of the treatment element, and retrieval

  2. Clinical Success [ Time Frame: 6 Months ]
    The resumption of normal dialysis for at least one session.

  3. Procedural Success [ Time Frame: 6 Months ]
    Composite of anatomic and clinical success

  4. Target Lesion Primary Patency [ Time Frame: 6, 9 and 12 Months ]
    The time interval of uninterrupted patency from initial study treatment to the next thrombosis or intervention performed on the target lesion

  5. Circuit Primary Patency [ Time Frame: 6, 9, and Months ]
    The time interval from initial study treatment to the next access thrombosis or intervention performed within the vascular access circuit.

  6. Assisted Primary Patency [ Time Frame: 6, 9, and 12 Months ]
    The time interval from initial study treatment to occlusion (thrombosis) of the vascular access circuit.

  7. Access Secondary Patency [ Time Frame: 6, 9, and 12 Months ]
    The time interval from initial study treatment to abandonment of the vascular access circuit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Arteriovenous Fistula or Arteriovenous Graft Stenosis, eligible for FLEX/Angioplasty treatment.

Inclusion Criteria:

  1. Hemodialysis patient currently scheduled to undergo an intervention of their arteriovenous fistula or graft due to clinical or hemodynamic abnormalities.
  2. The patient is ≥18 years of age. Patient is legally competent, has been informed of the study, voluntarily agrees to participate, and has signed the inform consent form.
  3. The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
  4. The patient understands the study and is willing and able to comply with follow-up requirements.
  5. The patient is willing to provide informed consent.

Exclusion Criteria:

  1. The patient has a known or suspected systemic infection.
  2. The patient has a known or suspected infection of the hemodialysis graft.
  3. The patient has an untreatable allergy to radiographic contrast material.
  4. In the opinion of the operating physician, the patient's hemodialysis access is unsuitable for endovascular treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04070365

Layout table for location information
United States, Alabama
Grandview Medical Center
Birmingham, Alabama, United States, 35243
Flowers Hospital
Dothan, Alabama, United States, 36305
University of Alabama
Tuscaloosa, Alabama, United States, 35487
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Missouri
SSM Health SLU
Saint Louis, Missouri, United States, 63117
United States, North Carolina
FirstHealth Moore Regional Hospital
Pinehurst, North Carolina, United States, 28374
United States, Ohio
JOBST Vascular Institute
Toledo, Ohio, United States, 43606
United States, South Carolina
Dialysis Access Institute
Orangeburg, South Carolina, United States, 29118
United States, Virginia
Richmond Vascular
Richmond, Virginia, United States, 23235
Sponsors and Collaborators
VentureMed Group Inc.
Layout table for investigator information
Principal Investigator: John Aruny, MD Dialysis Access Institute
Layout table for additonal information
Responsible Party: VentureMed Group Inc.
ClinicalTrials.gov Identifier: NCT04070365    
Other Study ID Numbers: AV2019
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: May 31, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Arteriovenous Fistula
Arteriovenous Malformations
Vascular Fistula
Peripheral Arterial Disease
Constriction, Pathologic
Pathological Conditions, Anatomical
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities